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Abstract
MRCKa and MRCKb (myotonic dystrophy kinase-related Cdc42-binding kinases) belong to a subfamily of Rho GTPase
activated serine/threonine kinases within the AGC-family that regulate the actomyosin cytoskeleton. Reflecting their roles in
myosin light chain (MLC) phosphorylation, MRCKa and MRCKb influence cell shape and motility. We report further evidence
for MRCKa and MRCKb contributions to the invasion of cancer cells in 3-dimensional matrix invasion assays. In particular, our
results indicate that the combined inhibition of MRCKa and MRCKb together with inhibition of ROCK kinases results in
significantly greater effects on reducing cancer cell invasion than blocking either MRCK or ROCK kinases alone. To probe the
kinase ligand pocket, we screened 159 kinase inhibitors in an in vitro MRCKb kinase assay and found 11 compounds that
inhibited enzyme activity .80% at 3 mM. Further analysis of three hits, Y-27632, Fasudil and TPCA-1, revealed low
micromolar IC50 values for MRCKa and MRCKb. We also describe the crystal structure of MRCKb in complex with inhibitors
Fasudil and TPCA-1 bound to the active site of the kinase. These high-resolution structures reveal a highly conserved AGC
kinase fold in a typical dimeric arrangement. The kinase domain is in an active conformation with a fully-ordered and
correctly positioned aC helix and catalytic residues in a conformation competent for catalysis. Together, these results
provide further validation for MRCK involvement in regulation of cancer cell invasion and present a valuable starting point
for future structure-based drug discovery efforts.
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Introduction
Tumor cell metastasis is a multi-step process driven by dynamic
reorganization of the actomyosin cytoskeleton and remodeling of
the extracellular matrix that allows cells to cross tissue boundaries
and spread via blood and lymphatic vessels to distal regions of the
body [1]. Members of the Rho GTPase family are key regulators
of the actomyosin cytoskeleton required for the processes
associated with invasion and metastasis [2]. The bundling and
contraction of actin-myosin fibers provides the force required for
cell motility and invasion [1]. On this basis, downstream effector
proteins such as the Rho-regulated ROCK1 and ROCK2 protein
kinases that directly impact upon actomyosin contractility have
emerged as attractive potential targets for anti-metastatic thera-
peutics [3,4]. ROCK inhibitors have been shown to reduce the
invasive ability of tumor cells in vitro and to prevent the in vivo
dissemination of tumor cells including melanoma, fibrosarcoma,
liver, breast, lung and prostate cancer [5–11].
Recent research has shown that there are multiple modes of
individual tumor cell invasion with differing sensitivities to ROCK
inhibition [12–14]. Cells that migrate through 3-dimensional (3-D)
extracellular matrix (ECM) with a rounded morphology (also
known as amoeboid invasion) are more dependent upon ROCK
activity, whereas cells that invade using elongated actin-rich
protrusions (also called mesenchymal invasion) are relatively
insensitive to ROCK inhibition [15–18]. However, both invasion
modes are dependent upon the contractile force generated by
myosin ATPase activity [17], indicating that regulators of
actomyosin function in addition to ROCK are involved.
Cdc42 is a member of the Rho GTPase protein family that
plays key roles in actomyosin cytoskeletal organization and cell
migration through effector proteins including the myotonic
dystrophy kinase-related Cdc42-binding kinases a and b (MRCKa
and MRCKb) [19]. Both ROCK and MRCK belong to the AGC
kinase family, and MRCK can be further classified into the
myotonic dystrophy protein kinase (DMPK) subfamily. MRCKa
and MRCKb are 190 kDa multi-domain proteins expressed in a
wide range of tissues, with ,80% sequence identity across their
kinase domains. ROCK and MRCK kinases share ,45–50%
sequence identity homology over the N-terminal kinase domains,
which is reflected in their shared abilities to phosphorylate a
similar set of substrates (such as the myosin binding subunit
(MYPT1) of the myosin light chain (MLC) phosphatase complex
[17,20–22]). However, the C-terminal regulatory regions of
ROCK and MRCK are distinctly different. Importantly, it has
been observed that actomyosin contractility required for the
invasion of cells with elongated mesenchymal morphology is
dependent on Cdc42-MRCK signaling [17]. In such cells, which
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knockdown of MRCK had some effect on inhibiting invasion
while the combination of MRCK knockdown along with ROCK
inhibition more effectively inhibited invasion and caused cells to
adopt a spherical, non-blebbing morphology. These data indicate
that during elongated mesenchymal invasion, ROCK and MRCK
regulate independent and co-operative pathways that collaborate
in a non-compensatory manner. Given that there appears to be
considerable plasticity in the abilities of tumor cells to interchange
between elongated and rounded modes of tumor cell invasion in
response to varying environmental circumstances [12–14], one
potential anti-invasion strategy would be to simultaneously target
ROCK and MRCK activity in order to inhibit multiple invasion
modes and to counteract tumor cell adaptability.
Further data supporting the strategy of simultaneous ROCK
and MRCK inhibition comes from organotypic cell culture
systems used to examine ECM invasion by co-cultures of
squamous cell carcinoma (SCC) and cancer-associated stromal
fibroblasts (CAF) [23]. SCC cells form an epidermal-like layer
when grown on a three-dimensional collagen matrix, within which
embedded CAFs are able to create paths in the collagen layer that
enable SCCs to leave the epidermal layer and invade. The ability
of tumor derived fibroblasts to generate paths is dependent on
ROCK activity to remodel the matrix, while the ability of the
SCCs to move through the CAF-generated paths can be blocked
by MRCK knockdown [23]. The critical contribution of MRCK
in collective invasion apparently is to provide actomyosin
contractility around the periphery that helps to maintain cohesion
of the cell collective [23,24]. These data indicate that as well as
blocking the ability of tumor cells to alternate between invasion
modes, blocking MRCK and ROCK together would target
different processes that co-operate to promote tumor cell invasion.
In this study we have confirmed that the greatest inhibition of 3-
D ECM invasion by MDA MB 231 breast cancer cells occurs with
the combined inhibition of MRCK and ROCK. To examine the
structural basis of MRCK activity and to explore the potential for
developing specific inhibitors, we screened a collection of kinase
inhibitors and identified several that inhibited MRCK with low
micromolar IC50 values. Furthermore, we determined the
structure of MRCKb in complex with two ATP-competitive
inhibitors, namely Fasudil and TPCA-1. These results and crystal
structures provide valuable starting points for the development of
compounds that could potentially be used as anti-metastatic
therapeutics.
Results
Combined MRCK and ROCK inhibition reduces
3-dimensional matrix invasion
The contribution of MRCK to tumor cell invasion was
examined by knocking down both MRCKa and MRCKb in
MB 231 breast cancer cells and determining the effects in a 3-
dimensional inverse matrigel invasion assay [25]. The combined
MRCKa plus MRCKb knockdown could be achieved either with
two siRNA duplexes targeting each mRNA transcript
(MRCKa+b) or with a single siRNA duplex (MRCKa/b) that
targets both (Figure 1A). Following plating on the underside of
Transwell inserts containing a thick layer of matrigel and allowing
5 days for invasion through the porous filter and into the matrigel,
the extent of MDA MB 231 cell invasion was determined by fixing
and staining cells with propidium iodide, followed by confocal
microscopic optical sectioning at 10 mm intervals (Figure 1B). The
combined knockdown of MRCKa/b with two independent
doubly-targeting siRNA duplexes significantly reduced invasion
relative to non-targeted control (NTC) siRNA transfected cells
(Figure 1C). Treatment of NTC transfected cells with ROCK
inhibitor Y-27632 also significantly reduced invasion, while the
combination of MRCKa/b knockdown plus Y-27632 treatment
was significantly more effective than either MRCKa/b knock-
down or Y-27632 treatment alone (Figure 1C). Given the potential
for off-target effects of Y-27632, particularly on highly homolo-
gous kinases such as MRCK, we knocked down ROCK 1 and/or
ROCK2 to corroborate the effects of ROCK inhibition
(Figure 1D). The individual knockdowns of ROCK1 or ROCK2,
as well as the combined knockdown of ROCK1+ROCK2 or
MRCKa/b, were sufficient to significantly inhibit invasion above
40 mm (Figure 1E). When MRCKa/b knockdown was combined
with either ROCK1 or ROCK2 knockdown the effect was
significantly greater than for any of these conditions alone
(Figure 1E). The complete combination of MRCKa/b with
ROCK1+ROCK2 knockdown was most effective of all, being
significantly more inhibitory than any of the other combinations
(Figure 1E). These data support the conclusion that the most
effective method to reduce tumor cell invasion is through the
combined inhibition of ROCK and MRCK signaling.
Kinase inhibitor screen
In order to identify tool compounds and to begin building
structure-activity relationship information on MRCK inhibitors,
we screened 159 kinase inhibitors at 30 mM and 3 mM in MRCKb
in vitro kinase assays at the enzyme Km for ATP. We found that
15% (24/159) of the inhibitors resulted in .80% inhibition at
30 mM (Figure 2A) and 7% (11/159) inhibited .80% at 3 mM
(Figure 2B and Table 1). In some instances, inhibition at 30 mM
was lower than at 3 mM, which was likely due to inhibitors
partially coming out of solution at higher concentration. These
experiments revealed that some ROCK inhibitory compounds
also inhibited MRCKb (e.g. H-89 99.1% inhibition at 30 mM and
79.3% inhibition at 3 mM; Fasudil 95.4% inhibition at 30 mM and
63.6% at 3 mM; Y-27632 96.6% inhibition at 30 mM and 83.5%
at 3 mM), consistent with the high homology between the MRCK
and ROCK kinase domains. Interestingly, the reportedly IKK2-
selective inhibitor TPCA-1 [26] was also reasonably effective at
inhibiting MRCKb (88.9% inhibition at 30 mM and 50.1% at
3 mM). To more comprehensively characterize the effects of
selected inhibitors, 10 point dose-response analysis over 5 log10
drug concentrations were carried out for Y-27632, TPCA-1 and
Fasudil for MRCKa and MRCKb. These assays revealed
comparable rank orders of potencies with Y-27632.TPCA-
1.Fasudil for both MRCKa and MRCKb (Figure 2C and 2D,
Table 2). The ability of Fasudil to inhibit MRCK activity suggests
that this inhibitor may not be as strictly selective for ROCK
kinases as had previously been indicated [27], in agreement with
the reported incomplete selectivity of this compound [28]. The
observation that Fasudil did not effectively inhibit MRCK activity
in Amano et al. [27] likely results from differences in assay
conditions (e.g. .140 times higher ATP concentration).
MRCKb Structure
Active conformation despite lack of phosphorylation. The
overall structure bears great resemblance to the closest AGC kinase
homologues, DMPK and ROCK1/2. The quaternary structure of
the MRCKb kinase domain is dimeric, with both the N- and C-
termini involved in the dimerization interface (Figure 3A and 3B). In
both monomers, the activation loop is well-ordered and in a
conformation that does not impede access to the nucleotide or
substrate binding sites, thus resembling an active kinase
conformation. As in the ROCK and DMPK kinase domain
MRCK Crystal Structure in Complex with Inhibitors
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relative to that in PKA [32] allows a small antiparallel b-sheet to be
produced from a part of the activation loop and a part of the aEF/aF
loop (Figure 3B and 4A). The conservation of these structural features
between MRCK and AGC kinase homologues implies that the
interactions between the activation loop and the aEF/aF loop are
important in stabilizing the activation loop in the open conformation.
The active conformation of the activation segment is additionally
stabilized by a hydrogen bond formed by the catalytic loop (HRD)
arginine (R199) with the main chain carbonyl of S221 located C-
terminally to the DFG motif. The catalytic aspartate of the HRD
motif (D200) is in a suitable position for catalysis. The helix aCi n
Figure 1. Inhibition of 3-D matrigel invasion by MDA MB 231 cells following MRCK and ROCK inhibition. (A) Knock-down of MRCKa and
MRCKb individually or in combination. Double knockdown was achieved either by combining separate siRNAs (MRCKa+b) or single siRNA duplexes
that target both kinases (MRCKa/b). NTC=non-targeting control. (B) Optical slices were obtained every 10 mm by confocal imaging. (C) Invasion
40 mm above the transwell filter surface was normalized to non-targeting control (NTC) siRNA transfected cells. Significant differences between
groups of columns indicated. (Average 6 SEM, n=3). MRCKa/b knockdown or ROCK inhibition with Y-27632 (Y) significantly decreased invasion, with
the combination of MRCKa/b knockdown and ROCK inhibition resulting in significantly more inhibition. (D) Effectiveness and specificity of ROCK1,
ROCK2 and MRCKab knockdowns. (E) The combination of MRCKa/b with ROCK1 and ROCK2 knockdown individually or in combinations were tested
for their effects on 3-D matrigel invasion. ROCK1, ROCK2 or ROCK1+ROCK2 combination were able to significantly inhibit invasion. However,
additional MRCKa/b knockdown significantly increased the inhibition of invasion in each instance. (Average 6 SEM, n=3).
doi:10.1371/journal.pone.0024825.g001
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PLoS ONE | www.plosone.org 3 September 2011 | Volume 6 | Issue 9 | e24825Figure 2. Inhibition of MRCK activity by kinase inhibitors. A collection of 159 kinase inhibitors were tested for their ability to inhibit MRCKb
activity in vitro at (A)3 0mM and (B)3mM. Pie charts represent the proportion inhibiting .80% at each concentration. Inhibition of (C) MRCKa or (D)
MRCKb activity by Y-27632, TPCA-1 and Fasudil. Both kinases were inhibited by these compounds, although some differences in sensitivity were
apparent.
doi:10.1371/journal.pone.0024825.g002
Table 1. Inhibitors of MRCKb in vitro.
Inhibitor Inhibition at 3 mM (%) Inhibition at 30 mM( % )
Alsterpaullone 90.7 78.4
Alsterpaullone, 2-Cyanoethyl 98.4 94.8
Bisindolylmaleimide I 87.9 ND
Cdk1 Inhibitor, CGP74514A 87.2 100
Cdk1/2 Inhibitor III 100 100
Go ¨ 6983 88.6 65.1
K-252a, Nocardiopsis sp. 87.3 98.4
PKR Inhibitor 80.1 100.5
Ro-32-0432 85.2 68.2
Staurosporine 98.6 100
doi:10.1371/journal.pone.0024825.t001
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structure, and the salt bridge between aCa n db3 that is an indicator
of an active kinase conformation is present (residues E124 and K105).
It has been previously reported that MRCK requires dimeriza-
tion and trans-autophosphorylation for activation, with mutational
analysis suggesting important regulatory roles of phosphorylation
sites at S234, T240, and T403 on MRCKa [33] (S233, T239 and
T402 in MRCKb respectively). As with the structures of other
related AGC kinases [29,30], no density consistent with phos-
phorylation was observed at these conserved residues in the
MRCKb structure. Furthermore, other AGC kinases, such as
DMPK and ROCK, have been found to have enzymatic activity
despite the lack of phosphorylation.
Conserved dimerization domain. Size-exclusion chroma-
tography indicated that MRCKb elutes as a dimer (data not
shown). The crystallographic asymmetric unit contains two
molecules of the MRCKb kinase domain, locked in a conserved
intermolecular interaction that represents the biological dimer
interface. As in the structures of the related AGC kinases, the
regions of MRCKb involved in the dimer interface are the four N-
terminal helices as well as the C-terminus of the kinase domain
(Figure 3A and 4B).
The buried accessible surface area in the MRCKb dimer is
2550 A ˚ 2, while those of ROCK1 and DMPK are 2100 A ˚ 2 and
1650 A ˚ 2 respectively (calculated using the MSD-PISA server [34]
(http://www.ebi.ac.uk/msd-srv/prot_int/pistart.html). The differ-
ence between MRCKb and DMPK can be explained by the
extended a1-helix seen in the former, spanning 14 residues in
comparison to only 6 residues in DMPK. The differences between
ROCK1 and MRCKb are more subtle, and the length of the a1-
helix is very similar in both proteins. The C-terminus of MRCKb
can be traced further in electron density than that of ROCK1,
thus contributing to the increased buried surface at the interface
(Figure 3A).
Conserved binding of the C-terminal tail to the N-
terminal lobe - the hydrophobic motif. Dimerization is
facilitated through the binding of the C-terminal tail of the kinase
domain to a groove in the N-terminal lobe (Figure 3A and 4B).
This arrangement is a general feature of AGC kinases, where a
groove is created in the N-terminal lobe by insertion of a small a-
helix, which causes a separation of helix aC and strand b4. The C-
terminus of the protein wraps around the N-terminal lobe to allow
the binding of the hydrophobic motif on the C-terminal tail
between aC and b4. This binding has occurred despite the lack of
phosphorylation at the hydrophobic motif, with two pairs of polar
residues in that are in hydrogen bonding distance from each
others, namely E28-T404 and D32-T402 (Figure 4B). This
probably represents a phosphorylation-independent stabilization
mechanism for the hydrophobic motif in this family, as previously
suggested for DMPK [28].
Binding of inhibitors to the active site of MRCKb. Both
of the compounds crystallized here, Fasudil and TPCA-1, bind to
the hinge region of the active site of MRCKb (Figure 5). Fasudil
and its derivatives have been previously crystallized with a number
of AGC kinases, including ROCK1 and ROCK2 [30,31]. The
binding mode observed with MRCKb does indeed reflect those
observed in previously determined structures. The isoquinoline
moiety forms a hydrogen bond to the hinge backbone of residue
Y156 (Figure 5A). The homopiperazine ring further enhances the
binding to the active site by linking the backbone of D204 and side
chain of N205. These contacts are effectively identical to those
seen in the Fasudil-ROCK complexes, and this is also reflected in
equivalent IC50 values that have been obtained for these enzymes.
There are two additional Fasudil molecules visible in the
asymmetric unit, stacked between symmetry-related protein
molecules (Figure 3A). Both of the molecules form hydrogen
bonds to residue E252 but this binding site is unlikely to exist in
solution as the sides of the binding cavity stacking the compound
do not belong to a biologically relevant protein complex.
Consequently, the binding observed at this location is likely to
be non-specific and an artifact of the crystallization process.
TPCA-1, an inhibitor of IKK-2 [26], has not been previously
crystallized with a kinase domain. This molecule makes hinge
hydrogen bonding interactions through the amide group to the
main chain of Y156 (Figure 5B). Furthermore, the carbamoyla-
mino-moiety makes an additional hydrogen bond to the main
chain of D154, and could further contribute to binding affinity
through water-mediated hydrogen bonds. The fluorophenyl group
points out from the active site.
An overlay of the two compounds indicates that they occupy
similar space within the hinge-binding region, with both the
homopiperazine ring of Fasudil and fluorophenyl moiety of
TPCA-1 pointing out from the active site groove in a similar
direction (Figure 5C).
Discussion
Previous studies have shown that the combination of MRCK as
well as ROCK inhibition has greater effects in blocking the
invasiveness of tumor cells than inhibition of either kinase alone
[17]. Similarly, the combined requirement for ROCK and
MRCK as regulators of actomyosin contractility has been
identified in ephrinB2-Fc induced endothelial cell retraction [35]
and during C. elegans embryonic elongation [36]. Interestingly, the
combination of ROCK and MRCK was also identified as being
important regulators of human keratinocyte proliferation, al-
though the mechanism for these observations was not established
in this study [37]. In addition, MRCK has been shown to
independently contribute to tumor cell invasion by contributing to
the formation of single-cell invasion tunnels (SCIT) in 3D collagen
matrices produced by membrane-type-1 matrix metalloproteinase
activity [38] and by allowing squamous cell carcinoma cells to
follow SCITs made by cancer-associated fibroblasts [23]. These
studies indicate that there a number of ways that MRCK, either
alone or in combination with ROCK, contributes to cancer.
Although there is information about increased MRCK expression
in tumors [39], it may also be the case that MRCK activity rather
than expression is altered in cancers. Similar to the activating
mutations identified in ROCK1 [40], sequencing of cancer
genomes revealed mutations in MRCKa and MRCKb that
would likely increase their specific activity. The activity of Rho
family GTPases such as Cdc42 may be up-regulated in tumor cells
via increased protein expression [41,42] or by increased activation
from extracellular signals in the tumor environment (such as
Table 2. IC50 values obtained for Fasudil, TPCA-1 and Y-27632
in vitro.
Inhibitor IC50 (mM)
MRCKa MRCKb
Fasudil 3.1360.41 1.9260.36
TPCA-1 1.0460.06 1.6960.13
Y-27632 0.3760.05 0.4760.03
doi:10.1371/journal.pone.0024825.t002
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situations in which enhanced MRCK activity contributes to
cancer growth and progression.
These findings would make it seem logical that the best course
of action would be to develop inhibitors that simultaneously
inhibited MRCK and ROCK. However, ROCK inhibitors have
been shown to have profound effects on blood pressure that could
present dose-limiting adverse cardiovascular effects [43]. It has
been suggested that these effects are mediated by ROCK1,
therefore, ROCK2 selective inhibitors have been developed to
circumvent the adverse effects associated with non-isoform specific
ROCK inhibitors [44–46]. If it were possible to avoid hypotensive
Figure 3. Structure of dimeric MRCKb. (A) Overall structure of the dimeric MRCKb shows the interactions of the two monomers at the
dimerization domain. The four Fasudil molecules observed per asymmetric unit are also shown, two bound to the surface of the protein (central) and
one bound to each of the ATP-binding sites (lateral). (B) A close-up of one monomer reveals a typical two-lobed kinase structure, with both the N-
terminus (orange) and the C-terminus (purple; disorganized loop shown as a dashed line) forming the dimerization domain. The glycine-rich loop
(blue) and activation loop (red) are fully ordered, and the aEF/aF-loop is also indicated (yellow). Fasudil is shown bound in the ATP-binding site.
doi:10.1371/journal.pone.0024825.g003
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ROCK2 over ROCK1, then it might also be possible to make
inhibitors that blocked both MRCK isoforms and ROCK2 with
selectivity over ROCK1. Given that ROCK inhibitors such as
Fasudil also bind to and inhibit MRCK (Figures 2, 3 5), making
inhibitors that potently block MRCK and ROCK should be
possible, although the additional selectivity over ROCK1 will be
challenging. [30,31]The structure of MRCKb reported in this
study will provide better understanding of differences between
AGC kinases and facilitate structure based development of specific
inhibitors.
Comparison of MRCK to other relevant AGC kinases
Development of MRCK-specific or MRCK/ROCK2-specific
inhibitors relies on the structural differences between the different
AGC kinases in question (Figure 6). MRCKa and MRCKb share
62% identity over the full-length sequence and 77% identity across
the kinase domain. The residues lining the nucleotide-binding site
Figure 4. Detailed views of intramolecular interations. (A) Interactions involved in the small antiparallel b-sheet formed from a part of the
activation loop (red) and a part of the aEF/aF loop (yellow). (B) Hydrogen bonding interactions involved in the stabilization of the hydrophobic motif
within the dimerization domain.
doi:10.1371/journal.pone.0024825.g004
MRCK Crystal Structure in Complex with Inhibitors
PLoS ONE | www.plosone.org 7 September 2011 | Volume 6 | Issue 9 | e24825Figure 5. Positions of Fasudil and TPCA-1 in MRCKb active site. (A) Structure of Fasudil bound to the active site of MRCKb. Hydrogen bonds
are marked with yellow dashed lines. The Fo–Fc omit map is shown contoured at 2s, with the inhibitor modeled in the density. In the topology
diagram, surface contour is shown with a gray dashed line and hydrogen bonds with blue dashed lines. Hydrophobic residues lining the cavity are
shown in light green circles, and polar residues with light magenta. Blue shading indicates solvent exposed ligand groups. (B) Structure of TPCA-1
bound to the active site of MRCKb.( C) Overlay of the structures of Fasudil and TPCA-1 bound to the active site of MRCKb.
doi:10.1371/journal.pone.0024825.g005
MRCK Crystal Structure in Complex with Inhibitors
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MRCK is unlikely to be achievable by ATP-competitive
inhibitors.
Selectivity over ROCK isoforms, on the other hand, would
seem more feasible considering the differences at the structural
level. ROCK2 and MRCKb are approximately 46% and 75%
Figure 6. Sequence alignment of MRCKb and the most closely related AGC kinases. Sequences have been truncated after the C-terminal
lobe. The conserved HRD and DFG motifs have been highlighted with red arrows, and the conserved salt bridge at the active site with green arrows.
Predicted phosphorylation sites have been indicated with magenta arrows, and the residues involved in hydrogen bonds between the C- and N-
termini at the dimerization domain are indicated by orange arrows.
doi:10.1371/journal.pone.0024825.g006
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has a proline in the hinge region, although this doesn’t seem to
have a major impact on the structure. Key substitutions between
ROCK2 and MRCKb are V153 (ROCK2)/T137 (MRCKb) and
M144 (ROCK2)/L128 (MRCKb). These differences could be
used to design selective inhibitors for MRCKb (Figure 7A).
ROCK1 and MRCKb share approximately 47% identity across
the kinase domain and 93% in the ATP site. There are only two
substitutions in the active site, one of which points out of the site.
The other is L128 (MRCKb)/M128 (ROCK1), resulting only in a
very subtle difference in surface topology (Figure 7B). Conse-
quently, achieving selectivity against ROCK1 might be challeng-
ing and possibly requires extending compounds out from the ATP-
binding site.
To conclude, the results shown in this study indicate that
development of highly potent and specific inhibitors of these AGC
kinases could be challenging, but the methods now available for
structural studies of both MRCK and ROCK kinases should allow
iterative drug development approaches.
Materials and Methods
Cell culture
MDA-MB-231-luciferase (Caliper LifeScience) were grown in
DMEM with 10% fetal bovine serum (FBS), 2 mM L-glutamine
plus 10 Units/ml penicillin and 10 mg/ml streptomycin at 37uCi n
5% CO2 in a humidified incubator.
siRNA Transfection
All siRNA reagents were obtained from Dharmacon RNA
Technologies. All siRNA sequences available on request. Oligo-
fectamine was used for transfection of siRNA on sub-confluent
cells, according to manufacturer’s instructions.
Cell extraction and immunoblot analysis
RIPA lysates were prepared as described previously [47]. Whole
cell lysates (60 mg) were separated by SDS-PAGE, transferred to
Protran nitrocellulose membranes (Whatman), probed with
primary antibodies and appropriate HRP-conjugated secondary
antibodies (Pierce). Blots were visualized using ECL (Pierce) or
Supersignal West Femto (Pierce) according to manufacturer’s
instructions. Antibodies were from: MRCKa (611584) was from
BD Transduction Laboratories; MRCKb (H00009578-A01) was
from Abnova; MRCKa/b (MANDM1 6G8) from Glenn Morris
(Centre for Inherited Neuromuscular Disease, Oswestry UK)
[48,49]; ROCK1 (61136) and ROCK2 (610623) were from BD
Transduction Laboratories.
Inverse invasion assays
Cell invasion assays were as previously described [25].
Complete Matrigel was thawed on ice, diluted 1:1 with PBS and
then 100 ml of diluted matrigel pipetted into Transwell inserts in a
24 well tissue culture plate and left to incubate for 30 minutes at
37uC to set. During this time cell suspensions of 3610
5 cells per ml
from each condition were prepared in their normal growth
medium. When the Matrigel had set, the Transwell inserts were
inverted and 100 ml of cell suspension pipetted onto the filter.
Transwell inserts were then carefully covered with the base of the
24 well tissue culture plate, making contact with each cell
suspension droplet, and the plate then incubated in the inverted
state for 4 hours to allow cell attachment. Following this time,
plates were turned right-side-up and each Transwell insert washed
with 361 ml serum-free DMEM and finally placed in a well in
containing any additional inhibitors as indicated. DMEM plus
10% FBS was gently pipetted on top of the set Matrigel/PBS
mixture and incubated for 5 days at 37uC. Propoidium iodide (PI)
was used to visualize nuclei following fixation with paraformalde-
hyde, cells were imaged by confocal microscopy with a 206
objective with optical Z-sections scanned at 15 mm intervals
moving up from the underside of the filter into the matrigel.
ImageJ software was used for quantification. Statistical analysis
was performed by ANOVA followed by Bonferroni’s post-hoc test
of significance, with p.0.05 selected as the cut-off.
Cloning and protein expression
The cDNA encoding the human MRCKb kinase domain
(residues 2–417) with an N-terminal (His)6 tag and TEV protease
cleavage site was codon optimized for expression in E. coli,
synthesized and cloned into the Nde I and EcoR I restriction sites
of pET21a (Novagen) by Blue Heron. MRCKb 2–417 was
expressed in E. coli BL21 (DE3). Transformed cells were grown in
Terrific Broth at 30uC until A600 nm reached 0.6–0.9, and
induced with 1 mM IPTG, followed by incubation at 18uC for 12–
15 hrs. Pelleted cells were resuspended in lysis buffer (50 mM
Figure 7. An overlay of MRCKb (green) with ROCK2 (A; cyan)
and ROCK1 (B; magenta) highlights the very subtle structural
differences that could be exploited in developing specific
inhibitors. The surface shown is the nucleotide binding cavity of
MRCKb, with Fasudil bound at the ATP binding site. Apart from the
highlighted residues, the ATP binding sites of the three kinases are
identical at sequence level.
doi:10.1371/journal.pone.0024825.g007
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ole, 0.05% mercaptoethanol, 1% phosphatase inhibitor cocktails 1
& 2 [Sigma], Protease inhibitor cocktail [Roche EDTA-free]) and
lysed by sonication. Following centrifugal clarification (48,0006g
for 30 min), supernatant was incubated with Ni-NTA Sepharose 6
FF beads (GE Healthcare) for 2.5 hr at 4uC. Weaker binding
components were sequentially removed with 20 mM imidazole,
40 mM imidazole or 80 mM imidazole in ‘wash buffer’ (50 mM
Hepes pH 7.5, 500 mM NaCl, 0.5 mM MgCl2, 0.05% mercap-
toethanol). Beads were packed into a XK16/60 column (GE
Healthcare) before bound protein was step eluted with 500 mM
imidazole in ‘Wash Buffer’. Fractions were analyzed by UV,
pooled and purified further by size exclusion chromatography
(HiLoad 26/60 Superdex) using crystallization buffer (25 mM
Hepes pH 7.5, 150 mM NaCl, 1 mM MgCl2, 1 mM DTT).
Fractions containing dimeric MRCKb were pooled, concentrated
(Vivaspin 6, 10K cutoff), flash frozen and stored at 280uC.
Crystallization and data collection
Crystals of MRCKb 2–417 were obtained by incubating the
protein (,15 mg/mL concentration) with 1 mM of inhibitors
(prepared from 50 mM DMSO stocks) overnight and setting up
commercial crystallization screens the following morning. Plate-
like crystals were observed after the protein was incubated at 4uC
in hanging drops over well solution consisting of 15–25%
PEG3350, 0.1 M BisTris pH 5.6, 0.2 M Ammonium Sulfate
and 0.1 M Potassium/Sodium Tartrate. Crystals were frozen in
well solution supplemented with 20% ethylene glycol. Data was
collected at Diamond and Soleil.
Data processing and structure determination
Data were processed using Mosflm [50]. The data collection
statistics are presented in Table 3. The structure of MRCK b was
solved using the structure of DMPK as the search model for
molecular replacement using Phaser [51]. Refinement was carried
out using Refmac [52] and the structures were built by using
COOT [53].
Enzyme assays
Activity assays for MRCKa and b were performed using an
IMAP fluorescence polarization assay kit (Molecular Devices Inc.).
8–12 nM MRCKa or MRCKb (Millipore) was incubated for
60 minutes at room temperature with 100 nM FAM-S6-ribosomal
protein derived peptide (Molecular Devices Inc.) in the presence of
0.7 mM ATP and 0.5 mM Mg
2+ in 20 mM Tris buffer (pH 7.4)
containing 0.01% Tween-20 and 1 mM DTT. Dose response
inhibition analyses were performed over a drug concentration
range from 0.002–40 mM, and single point inhibition was assessed
at 3 or 30 mM drug. Kinase reactions were stopped with 2 assay
volumes of 0.25% (v/v) IMAP binding reagent in 16 IMAP
binding buffer A (Molecular Devices Inc.). After two hours
incubation to allow binding reagent to bind phosphorylated
peptide, fluorescence polarization was measured on a PHERAstar
plate reader (BMG Labtech GmbH) at excitation and emission
wavelengths of 485 nm and 520 nm respectively. Percent
inhibition was calculated using no inhibitor and no enzyme
controls for 0 and 100% inhibition, respectively.
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